Daudén Tello, EAlonso Suárez, JBeltrán Catalán, EBlasco Maldonado, CHerrero Manso, M CJiménez Morales, AMarín-Jiménez, IMartín-Arranz, M DGarcía-Merino, APorta Etessam, JRodríguez-Sagrado, M ARosas Gómez de Salazar, JTrujillo Martín, ESalgado-Boquete, L2023-02-092023-02-092020-09-07http://hdl.handle.net/10668/16239We present a series of general and specific recommendations based on pathophysiologic considerations for managing the most common adverse effects of apremilast that lead to treatment discontinuation: diarrhea, nausea, and headache. The recommendations are based on a review of the literature and the experience of a multidisciplinary team of 14 experts including dermatologists, rheumatologists, neurologists, gastroenterologists, pharmacists, and nurses. We propose a series of simple algorithms that include clinical actions and suggestions for pharmacologic treatment. The adverse effects of apremilast can be managed from a multidisciplinary approach. The purpose of optimizing management is to bring clinical benefits to patients.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Adverse effectsApremilastCefaleaDiarreaDiarrheaEfectos adversosHeadacheNauseaNáuseasPsoriasisCombined Modality TherapyDiarrheaDisease ManagementHeadacheHumansNauseaPatient Care TeamPhosphodiesterase 4 InhibitorsPractice Guidelines as TopicPsoriasisThalidomideresearch article32910923open access10.1016/j.ad.2020.08.0072173-5778https://doi.org/10.1016/j.ad.2020.08.007